Maria Beatrice Alora-Palli, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coal Tar | 2 | 2010 | 17 | 0.750 |
Why?
|
| Dermatologic Agents | 4 | 2015 | 278 | 0.660 |
Why?
|
| Calcitriol | 2 | 2010 | 298 | 0.650 |
Why?
|
| Psoriasis | 3 | 2011 | 898 | 0.470 |
Why?
|
| Photosensitivity Disorders | 2 | 2020 | 78 | 0.210 |
Why?
|
| Tretinoin | 2 | 2015 | 517 | 0.190 |
Why?
|
| Administration, Cutaneous | 3 | 2012 | 711 | 0.180 |
Why?
|
| Skin Aging | 2 | 2017 | 127 | 0.170 |
Why?
|
| Single-Blind Method | 3 | 2015 | 1590 | 0.160 |
Why?
|
| Iontophoresis | 1 | 2015 | 74 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 2043 | 0.120 |
Why?
|
| Hyperpigmentation | 1 | 2015 | 112 | 0.110 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2013 | 42 | 0.110 |
Why?
|
| Nevus, Pigmented | 1 | 2015 | 219 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 1060 | 0.110 |
Why?
|
| Rosacea | 1 | 2012 | 49 | 0.100 |
Why?
|
| Clindamycin | 1 | 2012 | 139 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2013 | 836 | 0.090 |
Why?
|
| Nonprescription Drugs | 1 | 2010 | 116 | 0.090 |
Why?
|
| Phototherapy | 1 | 2011 | 377 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 397 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 15540 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2012 | 1065 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 39050 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2017 | 1641 | 0.050 |
Why?
|
| Dermatitis, Photoallergic | 1 | 2020 | 3 | 0.050 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2020 | 15 | 0.050 |
Why?
|
| Porphyrias | 1 | 2020 | 57 | 0.050 |
Why?
|
| Weight Loss | 1 | 2011 | 2622 | 0.050 |
Why?
|
| Contrast Media | 1 | 2013 | 5300 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2015 | 63114 | 0.040 |
Why?
|
| Urticaria | 1 | 2020 | 150 | 0.040 |
Why?
|
| Sunlight | 1 | 2020 | 325 | 0.040 |
Why?
|
| Recurrence | 1 | 2010 | 8340 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2020 | 392 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 5391 | 0.040 |
Why?
|
| Massachusetts | 1 | 2010 | 8663 | 0.040 |
Why?
|
| Facial Dermatoses | 1 | 2017 | 87 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2010 | 3022 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17446 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5686 | 0.030 |
Why?
|
| Lentigo | 1 | 2015 | 37 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2015 | 321 | 0.030 |
Why?
|
| Melanosis | 1 | 2015 | 78 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 9959 | 0.030 |
Why?
|
| Middle Aged | 8 | 2017 | 213383 | 0.030 |
Why?
|
| Mohs Surgery | 1 | 2015 | 197 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 11366 | 0.030 |
Why?
|
| Keratoacanthoma | 1 | 2012 | 33 | 0.030 |
Why?
|
| Warts | 1 | 2012 | 68 | 0.030 |
Why?
|
| Keratosis, Actinic | 1 | 2012 | 74 | 0.030 |
Why?
|
| Oximes | 1 | 2012 | 311 | 0.020 |
Why?
|
| Gels | 1 | 2012 | 427 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2012 | 371 | 0.020 |
Why?
|
| Adult | 6 | 2017 | 214055 | 0.020 |
Why?
|
| Dermatology | 1 | 2020 | 872 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2759 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2013 | 8324 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13695 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 12745 | 0.020 |
Why?
|
| Young Adult | 2 | 2017 | 56430 | 0.020 |
Why?
|
| Female | 8 | 2017 | 380194 | 0.020 |
Why?
|
| Quality of Life | 1 | 2010 | 12804 | 0.020 |
Why?
|
| Humans | 10 | 2020 | 744343 | 0.020 |
Why?
|
| Aged | 4 | 2017 | 163280 | 0.020 |
Why?
|
| Pyridones | 1 | 2012 | 712 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 1959 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Male | 6 | 2015 | 350118 | 0.020 |
Why?
|
| Indoles | 1 | 2012 | 1839 | 0.010 |
Why?
|
| Neoplasms | 1 | 2012 | 21683 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2020 | 77449 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8642 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2012 | 1938 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2012 | 12026 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 21746 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 29063 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 4034 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 19905 | 0.010 |
Why?
|
| Melanoma | 1 | 2012 | 5510 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 23338 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7181 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 57776 | 0.010 |
Why?
|
| United States | 1 | 2020 | 69872 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 29786 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 72290 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 35421 | 0.000 |
Why?
|